Latest news for Vaso (OTC:VASO) Stock

Vaso Corp is a medical technology company. It provides diverse product and service categories, including noninvasive monitoring and therapeutic devices, diagnostic imaging equipment, and information technology for enterprises and clinical customers. The company currently operates in three distinct business units namely IT; Professional sales and Equipment. It generates maximum revenue from the IT segment. IT segment focuses on healthcare IT and managed network technology services.

News

VASO

Vasomedical Receives FDA 510k Clearance on Two New Devices 

Vaso Corp

Earnings

VASO Q2 Revenue $20.226M Down From $20.323M YoY

AVHI

Medical Technology Company Vaso, Currently Trading On OTC Market, To List On Nasdaq Via SPAC Merger; Transaction Values Vaso At Pro Forma Equity Value Of $176M At $10 Per Share

<p>Vasomedical (OTC: VASO) today announced its receipt of U.S. FDA 510(k) clearance to market its Vasomedical-BIOX™ Model 2302 Combined 12-Channel ECG Holter/Ambulatory Blood Pressure Monitor and Model 1804 Ambulatory Blood Pressure Monitor. These new models complement the Company's already cleared Model 1305 3-Channel ECG Holter Monitor and Model 2301 Combined 3-Channel ECG Holter/Ambulatory Blood Pressure Monitor, and significantly expand its offering of BIOX series ambulatory patient monitoring products in the U.S. market under its exclusive North American Distributorship Agreement with BIOX Instruments Co., Ltd. based in Wuxi, China. </p>



Health Care

Press Releases

Vaso Corporation Announces Financial Results for Fourth Quarter and Full Year of 2023

Vaso Corporation Announces Financial Results for First Quarter 2024

Vaso Corporation Announces the Effectiveness of the Achari Ventures Holdings Corp. I Registration Statement on Form S-4

Vaso Corporation Announces Financial Results for Second Quarter 2024

Vaso Corporation Announces Date Change for Its Stockholders Meeting

Contracts

Vaso Corporation Announces Termination of Business Combination Agreement with Achari Ventures Holdings Corp. I

Vaso Corporation Announces Financial Results for Third Quarter 2024

General

Vaso Corporation CEO Reflects on a Year of Growth and Innovation in End-of-Year Letter Setting the Tone for a Promising 2025

Vaso Corporation Announces Executive Leadership Appointments & Names New Vice Chairman to the Board of Directors

Vaso

Vasomedical (OTC: VASO) today announced its receipt of U.S. FDA 510(k) clearance to market its Vasomedical-BIOX™ Model 2302 Combined 12-Channel ECG Holter/Ambulatory Blood Pressure Monitor and Model 1804 Ambulatory Blood Pressure Monitor. These new models complement the Company's already cleared Model 1305 3-Channel ECG Holter Monitor and Model 2301 Combined 3-Channel ECG Holter/Ambulatory Blood Pressure Monitor, and significantly expand its offering of BIOX series ambulatory patient monitoring products in the U.S. market under its exclusive North American Distributorship Agreement with BIOX Instruments Co., Ltd. based in Wuxi, China. 



Comments

Vaso

News

Latest news for Vaso (OTC:VASO) Stock

Wednesday, August 14, 2024

Thursday, December 07, 2023

Wednesday, June 29, 2011

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga